AQST Earnings Q2 2026: Aquestive Therapeutics Quarterly Results, Analysis & Outlook

Q2 2026 Financial Highlights

Revenue Performance

Aquestive Therapeutics reported total revenue of [Q2_REVENUE] for the second quarter of 2026, compared to [Q2_PRIOR_REVENUE] in Q2 2025 (per the company's earnings press release). This figure encompasses both product revenue from its commercialized therapies and royalty or licensing revenue generated through manufacturing and technology partnerships.

A key driver of the company's top-line performance has been Sympazan® (clobazam oral film), approved for the treatment of seizures associated with Lennox-Gastaut syndrome. Investors closely tracked Sympazan prescription trends throughout the quarter, as the product represents one of Aquestive's most important commercial-stage assets. Additionally, revenue contributions from manufacturing agreements — including the company's long-standing relationship for producing Suboxone® oral film — continued to play a role in the overall revenue mix.

Earnings Per Share and Profitability

The company reported GAAP earnings per share (EPS) of [GAAP_EPS] for Q2 2026, while adjusted EPS came in at [ADJ_EPS] (according to the company's quarterly filing with the SEC). Analysts had expected adjusted EPS of [CONSENSUS_EPS] heading into the report, per consensus estimates compiled by Wall Street analysts.

Operating expenses for the quarter totaled [OPEX], reflecting the company's ongoing investments in research and development as well as commercial infrastructure. R&D spending specifically came in at [RD_EXPENSE], a figure that underscores Aquestive's commitment to advancing its pipeline candidates through clinical development. Selling, general, and administrative (SG&A) expenses were [SGA_EXPENSE], influenced by commercialization efforts for existing products.

Aquestive's path to sustained profitability remains a focal point for investors. The company's gross margin stood at [GROSS_MARGIN]%, and management continues to emphasize operational leverage as product revenues scale. For a deeper look at how specialty pharma companies approach profitability milestones, see our guide to evaluating biotech and pharma earnings reports.

Cash Position and Balance Sheet

As of June 30, 2026, Aquestive reported cash, cash equivalents, and short-term investments of [CASH_POSITION] (per SEC filings). This compares to [PRIOR_CASH] at the end of the prior quarter. The company's cash burn rate is a critical metric, as it determines the operational runway available to fund ongoing R&D programs and commercial operations without the need for dilutive capital raises.

Total debt on the balance sheet stood at [TOTAL_DEBT], and the company's current ratio — a measure of short-term liquidity — was [CURRENT_RATIO]. Management addressed capital allocation priorities during the earnings call, including any plans for future financing activities or debt restructuring.

Pipeline and Product Updates

Sympazan and Commercial Products

Sympazan remains the cornerstone of Aquestive's commercial portfolio. During the Q2 2026 earnings call, management provided updated prescription volume data and discussed market penetration strategies for the Lennox-Gastaut syndrome treatment space. The oral film formulation offers a differentiated delivery mechanism compared to traditional oral tablets, which is particularly advantageous for patients — often children — who have difficulty swallowing conventional medications.

The competitive landscape for LGS treatments includes established therapies such as clobazam tablets, cannabidiol (Epidiolex), and other antiepileptic drugs. Aquestive's ability to expand Sympazan's market share depends on continued physician education, payer coverage expansion, and real-world evidence demonstrating the benefits of the oral film formulation.

Anaphylm™ (Epinephrine Oral Film)

One of the most closely watched pipeline assets is Anaphylm™, Aquestive's sublingual epinephrine film for the emergency treatment of anaphylaxis. This product candidate represents a potentially transformative opportunity, as it could offer a needle-free alternative to epinephrine auto-injectors like EpiPen — a market that has long been dominated by injectable delivery systems.

During the Q2 2026 update, management provided details on [ANAPHYLM_STATUS], including any regulatory milestones, clinical trial data readouts, or FDA interactions. If approved, Anaphylm could address a substantial unmet need among patients with severe allergies who are averse to self-injection, potentially opening up a multi-billion-dollar addressable market. For context on how FDA approval timelines affect pharma stock valuations, visit our analysis of biotech catalyst events.

Additional Pipeline Candidates

Beyond Anaphylm, Aquestive continues to leverage its PharmFilm technology platform to develop additional product candidates. The company has explored applications in CNS disorders and other therapeutic areas where oral film delivery could offer clinical or patient-experience advantages. Management discussed the status of early-stage and preclinical programs during the earnings call, including any new partnerships or licensing agreements that could generate non-dilutive funding.

The breadth of the PharmFilm platform is a key part of Aquestive's long-term investment thesis. Each successful product developed on the platform has the potential to validate the technology further and attract additional partnership opportunities from larger pharmaceutical companies.

Management Commentary and Guidance

During the Q2 2026 earnings call, CEO Keith Kendall and the executive team provided forward-looking commentary on the company's strategic priorities. Key themes from management's prepared remarks included [KEY_THEMES], along with updated financial guidance for the remainder of fiscal year 2026.

Management reiterated (or updated) full-year 2026 revenue guidance of [FY_GUIDANCE_REVENUE] and projected operating expenses in the range of [FY_GUIDANCE_OPEX] (according to the company's earnings presentation). The guidance reflects management's expectations for product revenue growth, potential milestone payments, and the timing of key pipeline catalysts.

Notably, management addressed questions from analysts regarding the competitive environment, pricing strategies, and the timeline for potential Anaphylm commercialization. Investors should pay close attention to any changes in tone or specificity compared to prior quarters, as such shifts often signal evolving confidence levels within the executive team.

Analyst Reactions and Wall Street Consensus

Following the AQST earnings Q2 2026 release, Wall Street analysts weighed in with updated ratings and price targets. The consensus analyst price target for AQST stands at [CONSENSUS_PT], representing [UPSIDE_DOWNSIDE]% from the current share price (per Bloomberg consensus data). The stock currently carries [BUY_RATINGS] buy ratings, [HOLD_RATINGS] hold ratings, and [SELL_RATINGS] sell ratings among covering analysts.

Several analysts highlighted [ANALYST_HIGHLIGHTS] as the most significant takeaways from the quarter. Bull-case arguments centered on the commercial potential of Anaphylm and the scalability of the PharmFilm platform, while bear-case concerns focused on the company's cash burn trajectory and the competitive risks facing Sympazan.

For investors looking to compare AQST's valuation metrics against industry peers, the stock currently trades at a price-to-sales ratio of [PS_RATIO] and a forward P/E of [PE_RATIO]. These figures should be contextualized within the broader specialty pharmaceutical sector, where high-growth companies often trade at premium multiples in anticipation of pipeline catalysts. Explore our specialty pharma stock screener for side-by-side comparisons.

Key Metrics at a Glance

Metric	Q2 2026	Q2 2025	Change
Total Revenue	[Q2_REVENUE]	[Q2_PRIOR_REVENUE]	[REVENUE_CHANGE]%
GAAP EPS	[GAAP_EPS]	[PRIOR_GAAP_EPS]	[EPS_CHANGE]
Adjusted EPS	[ADJ_EPS]	[PRIOR_ADJ_EPS]	[ADJ_EPS_CHANGE]
Gross Margin	[GROSS_MARGIN]%	[PRIOR_GROSS_MARGIN]%	[MARGIN_CHANGE] bps
Cash & Equivalents	[CASH_POSITION]	[PRIOR_CASH]	[CASH_CHANGE]
R&D Expense	[RD_EXPENSE]	[PRIOR_RD_EXPENSE]	[RD_CHANGE]%

What to Watch Going Forward

As investors digest the AQST earnings Q2 2026 report, several catalysts and risk factors warrant close monitoring in the coming quarters. First and foremost, regulatory progress on Anaphylm represents the single largest potential value driver for the stock. Any FDA acceptance of a New Drug Application (NDA), advisory committee meetings, or PDUFA dates could serve as major share-price catalysts.

Second, Sympazan's commercial trajectory will be instrumental in determining whether Aquestive can generate sufficient organic revenue to reduce its reliance on external financing. Prescription growth trends, payer coverage decisions, and competitive dynamics in the LGS treatment space all bear watching.

Third, Aquestive's cash position and capital allocation strategy will remain in focus. Investors should monitor quarterly cash burn rates and evaluate whether the company has sufficient runway to reach key inflection points without significant equity dilution. Any announcements regarding new partnerships, licensing deals, or non-dilutive funding would be viewed positively by the market.

Finally, broader macroeconomic conditions — including interest rate policy and investor appetite for small-cap biotech and pharmaceutical stocks — will continue to influence AQST's trading dynamics. Risk-tolerant investors may find the current setup compelling if they have conviction in the pipeline, while more conservative investors may prefer to wait for additional de-risking events before initiating or adding to positions. For more on building a diversified pharmaceutical portfolio, check out our biotech investing strategies guide.